Smoking Increases Carcinogenic Polycyclic Aromatic Hydrocarbons in Human Lung Tissue

Radoslav Goldman, Lindsey Enwold, Edo Pellizzari, James B. Beach, Elise D. Bowman, Shiva S. Krishnan, and Peter G. Shields

Abstract

Tobacco smoke is a major source of human exposure to polycyclic aromatic hydrocarbons (PAHs). The concentration of PAHs in lung tissue would reflect an individual’s dose, and its variation could perhaps reflect cancer risk. Eleven PAHs were measured in 70 lung tissue samples from cancer-free autopsy donors by gas chromatography–mass spectrometry. There were 37 smokers and 33 nonsmokers as estimated by serum cotinine concentration. The sum of PAH concentrations was higher in smokers than in nonsmokers. The mean age was 35 years (range, 15–65). The tissues were collected through a medical examiner’s office. Gender, race, age, and cause of death were determined by the medical examiner. The subjects died suddenly of injuries collected through a medical examiner’s office. Gender, race, age, and cause of death were determined by the medical examiner. The subjects died suddenly of injuries collected through a medical examiner’s office. Gender, race, age, and cause of death were determined by the medical examiner. The subjects died suddenly of injuries collected through a medical examiner’s office. Gender, race, age, and cause of death were determined by the medical examiner.

Introduction

BAP and other PAHs are ubiquitous genotoxins present in cigarette smoke, air, water, and food. Seventeen PAH compounds, including BAP, have been classified as laboratory animal carcinogens (1). Strong epidemiological (2) and laboratory (3) evidence, including site-specific hotspot mutations in the p53 tumor suppressor gene (4, 5), links these compounds to human lung cancer. PAHs are also implicated in other cancers including skin, head and neck, bladder, and colon (2).

The carcinogenicity of PAH compounds is mediated by DNA damage (3). The best-characterized pathway for genotoxicity of PAHs consists of covalent binding of the metabolically activated carcinogen to DNA bases to form DNA adducts (6). The DNA adducts are promutagenic lesions that can lead to mutations in oncogenes or tumor suppressor genes, if not repaired or otherwise eliminated (7). Concentration of DNA adducts is considered the biologically effective dose of the parent PAH (8). Because accumulation of parent PAH compounds in the lung tissue precedes formation of DNA adducts, it is intuitive that the lipophilic parent PAHs would be a good estimate of dose in the target organ.

Smoking yields of PAH compounds vary considerably based on the type of cigarette and human differences in smoking behavior. It was estimated by the FTC machine method that a smoker is exposed to about 1–30 μg/day/pack of cigarettes (9). PAH exposure also occurs from non-tobacco sources and can be assessed by environmental sampling or personal monitoring (10). Certain occupational exposures, e.g., coke-oven work, present a burden comparable with smoking. The air in urban areas can contain higher percentage of PAH compounds than the air in the countryside, especially in the winter. Our diet also contributes to exposure, especially from overcooked foods; it has been estimated that diet contributes 3 μg/day of total PAH intake, ~70% for a nonsmoker (11). The PAH exposure pattern is therefore complex, and analysis of the lung tissue can provide direct information difficult to estimate by other methods.

Our study determined the concentration of 11 PAHs in 70 lung samples of cancer-free subjects using a sensitive and robust GC-MS method (12). Six of the analyzed PAHs were classified previously as laboratory animal carcinogens (1). The study reports the analysis of individual PAHs as well as the sum of carcinogenic, noncarcinogenic, and total PAHs. The size (70 individuals) and scope (11 PAHs) of the study provide an evaluation of the effect of smoking, race, gender, age, and fat content on the accumulation of PAHs in the lung tissue.

Materials and Methods

Population Description. The population consisted of 70 cancer-free Caucasian and African-American autopsy donors (32 males and 38 females; 31 Caucasians, 36 African-Americans, and 3 Hispanics; 37 smokers and 33 nonsmokers). The mean age was 35 years (range, 15–65). The tissues were collected through a medical examiner’s office. Gender, race, age, and cause of death were determined by the medical examiner. The subjects died suddenly from multiple injuries in motor vehicle accidents (n = 23), gunshot wound (n = 13), and other causes (n = 34).

Cotinine. Smoking data were not consistently available at the time of death. Thus, we classified smokers on the basis of serum cotinine. This might lead to the misclassification of some smokers as nonsmokers because of the 48-h half-life of cotinine. But because these individuals died unexpectedly (e.g., trauma), it is unlikely that they changed their smoking patterns before death. Serum cotinine was determined by a RIA kit (STC Technologies, Bethlehem, PA) with modifications as reported (13). Subjects with a serum cotinine concentration >14 ng/ml were classified as smokers (14).

PAH Analysis. The GC-MS method was described elsewhere (12). Briefly, PAHs were extracted into hexane from 4 g of tissue after saponification. The extract was separated using a HP 6890 gas chromatograph (Agilent Technologies, Palo Alto, CA) on a Restek Rtx-5 MS 5% diphenyldimethylpolysiloxane column and analyzed by GC-MS HP 5973 mass spectrometer (Agilent Technologies) using selected ion monitoring mode. The GC-MS was calibrated by standard solutions containing all 11 target compounds at concentrations ranging from 0.5 to 50 pg/μl. The standard solutions also contained internal
PAHS in human lung tissue

Table 1. PAH concentrations in human lung tissue (n = 70)*

<table>
<thead>
<tr>
<th>PAH</th>
<th>Median</th>
<th>Mean</th>
<th>Minimum</th>
<th>Maximum</th>
<th>SD</th>
</tr>
</thead>
<tbody>
<tr>
<td>BEP</td>
<td>0.007</td>
<td>0.016</td>
<td>ND</td>
<td>0.321</td>
<td>0.052</td>
</tr>
<tr>
<td>BP</td>
<td>0.033</td>
<td>0.110</td>
<td>ND</td>
<td>1.783</td>
<td>0.293</td>
</tr>
<tr>
<td>CH</td>
<td>0.025</td>
<td>0.055</td>
<td>ND</td>
<td>0.645</td>
<td>0.105</td>
</tr>
<tr>
<td>FL</td>
<td>0.065</td>
<td>0.151</td>
<td>ND</td>
<td>1.574</td>
<td>0.250</td>
</tr>
<tr>
<td>PY</td>
<td>0.065</td>
<td>0.150</td>
<td>ND</td>
<td>2.162</td>
<td>0.293</td>
</tr>
<tr>
<td>Sum</td>
<td>0.195</td>
<td>0.482</td>
<td>0.040</td>
<td>6.318</td>
<td>0.925</td>
</tr>
<tr>
<td>Carcinogenic PAHs</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BA</td>
<td>0.030</td>
<td>0.055</td>
<td>ND</td>
<td>0.691</td>
<td>0.102</td>
</tr>
<tr>
<td>BAP</td>
<td>0.036</td>
<td>0.086</td>
<td>ND</td>
<td>1.479</td>
<td>0.216</td>
</tr>
<tr>
<td>BBF</td>
<td>0.032</td>
<td>0.058</td>
<td>ND</td>
<td>0.540</td>
<td>0.094</td>
</tr>
<tr>
<td>BKF</td>
<td>0.017</td>
<td>0.039</td>
<td>ND</td>
<td>0.528</td>
<td>0.087</td>
</tr>
<tr>
<td>DA</td>
<td>0.009</td>
<td>0.053</td>
<td>ND</td>
<td>1.112</td>
<td>0.149</td>
</tr>
<tr>
<td>IP</td>
<td>0.026</td>
<td>0.088</td>
<td>ND</td>
<td>1.475</td>
<td>0.242</td>
</tr>
<tr>
<td>Sum</td>
<td>0.150</td>
<td>0.379</td>
<td>ND</td>
<td>4.837</td>
<td>0.756</td>
</tr>
<tr>
<td>Total PAHs</td>
<td>0.345</td>
<td>0.861</td>
<td>0.071</td>
<td>11.155</td>
<td>1.659</td>
</tr>
</tbody>
</table>

* ng/g of wet tissue (ppb).

Results

The concentrations of PAH identified in lung tissue are shown in Table 1. About 45% of the detected total PAHs, on a ng/g basis, falls in the carcinogenic category. The relative mean abundance of the individual PAHs varied ~10-fold between the most (FL) and least (BE) abundant PAH. The data showed that none of the PAHs was detected in all of the tissues examined, but all of the PAHs were detected in at least some samples. Our analyses concentrated on the effect of smoking on PAH concentration in the lung tissue.

Using serum cotinine to classify smoking status, there were 37 smokers and 33 nonsmokers. As indicated by the Mann-Whitney U test, smoking increased the concentration of five PAHs (BA, BAP, BP, BKF, and IP; Table 2). Interestingly, four of six carcinogenic PAHs were statistically affected by smoking, whereas only one of five noncarcinogenic PAHs was statistically affected by smoking. The relative mean abundance of the individual PAHs varied 8-fold between the most (FL) and least (BE) abundant PAH. The data showed that none of the PAHs was detected in all of the tissues examined, but all of the PAHs were detected in at least some samples. Our analyses concentrated on the effect of smoking on PAH concentration in the lung tissue.

Significant differences were detected in at least some samples. Our analyses concentrated on the effect of smoking on PAH concentration in the lung tissue.
Fig. 1. Carcinogenic PAHs in nonsmokers, light smokers, and heavy smokers. Non-smokers were defined by cotinine levels <14 ng/ml. The median value of smokers (cotinine, 339 ng/ml) was used to separate medium and heavy smokers. Three outliers (one for each category) are out of scale of the graph and are not represented for clarity.

Discussion

The results demonstrate that smoking increases PAH concentrations ~2-fold, and those PAHs that are carcinogenic are present at higher concentrations. The risk for having higher carcinogenic PAHs compared with noncarcinogenic PAHs was >3-fold. Moreover, there was a dose-response relationship for smoking characterized by increasing serum cotinine. Men had a higher concentration of PAHs than women, although the smoking levels were equivalent. This was mostly explained by differences in African-Americans compared with Caucasians, although overall there was no difference between the races.

There have been several previous reports of PAH concentrations in tissues, but this study uses a more sensitive detection method, is more comprehensive, and is the first study to detect significant increases of BAP and other PAHs with smoking, including a dose-response relationship (16–19). These previous studies of PAHs in human tissues showed). This was also true for the separate analysis of race in the subcategories of males and females, with the exception of BEP which was higher in Caucasian females than in African-American females (n = 38; P = 0.049). When the influence of race was analyzed separately for the subgroup of smokers/non-smokers, DA was the only PAH significantly higher in African-American males compared with Caucasians, although overall there was no difference between the races.

The concentration of PAHs in the lung tissue of males compared with females was uniformly higher for both the carcinogenic and noncarcinogenic PAHs (Table 4), although there were similar percentages of male and female smokers, and the cotinine levels tended to be higher for the females compared with the males (borderline statistical significance). Almost every individual PAH was higher in males compared with females. Interestingly, the increase in males compared with females was mostly attributable to the subcategory of African-Americans (Table 5).

The Spearman R coefficient was used to analyze the correlation of age with PAH concentrations. Age correlated with the sum of the noncarcinogenic PAHs (r = 0.25; P = 0.03) but not the sum of the carcinogenic PAHs (r = 0.12; P = 0.32). For individual PAHs, only the concentrations of FL (r = 0.35; P = 0.002), PY (r = 0.29; P = 0.01), and BA (r = 0.28; P = 0.02) were significantly correlated with age; but the correlation coefficients are relatively small, and the association could be attributable to chance.

The average fat content of the lungs was 1.1%, with a range of 0.1 to 5.7% (data not shown). We did not find a significant correlation of any PAH, or sum of PAHs, with the fat content of the lung tissue.

Discussion

The results demonstrate that smoking increases PAH concentrations ~2-fold, and those PAHs that are carcinogenic are present at higher concentrations. The risk for having higher carcinogenic PAHs compared with noncarcinogenic PAHs was >3-fold. Moreover, there was a dose-response relationship for smoking characterized by increasing serum cotinine. Men had a higher concentration of PAHs than women, although the smoking levels were equivalent. This was mostly explained by differences in African-Americans compared with Caucasians, although overall there was no difference between the races.

There have been several previous reports of PAH concentrations in tissues, but this study uses a more sensitive detection method, is more comprehensive, and is the first study to detect significant increases of BAP and other PAHs with smoking, including a dose-response relationship (16–19). These previous studies of PAHs in human tissues.
report values that vary by two orders of magnitude, possibly because of different population characteristics (race and smoking status), extraction/quantitation methods (UV-Vis spectroscopy, fluorescence, and mass spectrometry), and other methodological differences (wet or dry tissue weight). Importantly, the majority of previous studies used cancer patients, and cancer status was shown to affect PAH concentration in tissues (17).

The concentration of BAP in lung tissue has been reported most frequently. Lodovici et al. (16) reported BAP and five other PAHs in 20 lung autopsy tissues, where BAP concentration correlated with BAP DNA-adducts. Seto et al. (17) analyzed BAP, BKF, and BP in 364 lung samples from both cancer-free and cancerous formalin-fixed autopsies. The authors found that cancer tissue contains higher PAH concentration than noncancerous tissue, and that, similar to this study, males have higher PAH concentrations in the lung than females. Tokiwa et al. (18) analyzed BAP in 158 lung tumor resections and proposed a correlation of the PAHs with environmental exposure. Tomingas et al. (19) analyzed 12 PAHs in 33 bronchial carcinoma tissues but detected only four of the PAHs. Only BAP was found in all tissues at high concentrations in that study.

It is interesting that four of five PAHs that were increased in smokers were classified previously as carcinogenic to animals (1). The steady-state in the lung tissue is defined by complex exposure, distribution, and metabolism processes that cannot be unequivocally defined in this study. There are several possible explanations why smoking increases carcinogenic PAHs more than the noncarcinogenic PAHs. A smoking-related increase in noncarcinogenic PAHs such as FL and PY, which seem to accumulate in the tissue with age, is too small and cannot be detected. Another explanation is that metabolic turnover is an important determinant of the steady-state and that smoking affects clearance of the PAHs indirectly through induction of metabolic enzymes. Smoking could also be a better source of carcinogenic PAHs than diet and the environment. However, a conclusion about the source of PAH cannot be made without detailed knowledge of individual exposures because the concentration of PAHs in the environment and in cigarette smoke vary considerably, depending on several factors (source of environmental pollution, type of cigarette, and smoking topography; ref. 9). Because we do not know what the brand types were of the smokers, we could not determine PAH levels in relation to FTC tar yields, to assess whether lower yield cigarettes actually produced lower dose levels. PAH concentrations were consistently higher in males than in females with significant differences for several individual hydrocarbons. This might be attributable to differences in the type of cigarettes smoked by men compared with women. Men tended to smoke heavier cigarettes with higher tar content at the time when exposures occurred.

Lung cancer rates differ by gender and race. The highest rates are observed for African-American males (112/100,000), followed by Caucasian males (73/100,000) and African-American and Caucasian females (46 and 43/100,000 respectively; Ref. 20). The PAH concentration in lung tissue from this study follows the same trend, although the difference by race was not statistically significant. African-American males have the highest PAHs (0.784 ng/g), followed by Caucasian males (0.407 ng/g), African-American females (0.308 ng/g), and Caucasian females (0.279 ng/g). In this study, African-American males had the highest concentration of almost every PAH examined, with Caucasian males second in many cases. This ranking suggests that African-American males have higher doses compared with other groups, or that metabolism/distribution of the PAHs in African-American males is different. It is known, for example, that African-Americans smoke mentholated cigarettes more frequently than Caucasians (21), which could affect exposures and inhalation patterns.

Fat content did not correlate with the PAH concentration in the lung tissue. We had expected to find a correlation because PAHs are lipophilic. This indicates that the PAHs do not accumulate in the fat of the lung. This result is consistent with a previous study that reported low PAH content in human fat tissue (22). The concentrations (<1 ppb) are much lower than, for example, concentrations of some polychlorinated biphenyl compounds (>1 ppm), which were shown to accumulate in the fat. It was shown that only the polychlorinated biphenyls, which are not metabolized by cytochrome P-450, accumulate in the adipose tissue (23). The available information on the metabolism of PAHs in human lung suggests that the metabolic activity might be an important determinant of the steady-state of the PAHs in the tissue (24).

There are several limitations to this study. The use of cotinine as a marker of smoking is well accepted, and higher levels are indicative of greater smoking levels (14). However, cotinine is only a marker of recent smoking and does not reflect lifetime exposure, whereas the PAH levels might reflect long-term exposure. Also, some individuals might be misclassified as nonsmokers if they stopped smoking recently. In this study group, because most died unexpectedly from trauma or cardiac disease, it is unlikely that the subjects actually changed their smoking habits. Another limitation is the small size of the study, making it difficult to assess race and gender issues combined, although it was large enough to reveal overall patterns. Finally, we were unable to actually obtain lifetime smoking histories, brand use, and other factors that would affect exposure. This information would be needed for additional interpretations of the data.

In conclusion, this study shows that smoking increases the concentration of BAP and other carcinogenic PAHs in the human lung tissue with a dose-response relationship. These methods could provide for direct assessment of actual exposure to PAHs in target organs, rather than estimating exposure through FTC tar yields or self-reported histories. Also, additional data would be useful to study the impact of metabolic phenotypes and/or cigarettes with different FTC tar yields and the exposures from cigarette-like devices on the steady-state of PAH in the lung tissue.

Acknowledgments

Special thanks to Dr. Haleem J. Issaq and Stephen D. Fox for the analysis of the fat content of the tissues.

References


6370


Smoking Increases Carcinogenic Polycyclic Aromatic Hydrocarbons in Human Lung Tissue

Radoslav Goldman, Lindsey Enewold, Edo Pellizzari, et al.

Cancer Res 2001;61:6367-6371.

Updated version

Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/61/17/6367

Cited articles

This article cites 22 articles, 5 of which you can access for free at:
http://cancerres.aacrjournals.org/content/61/17/6367.full#ref-list-1

Citing articles

This article has been cited by 3 HighWire-hosted articles. Access the articles at:
http://cancerres.aacrjournals.org/content/61/17/6367.full#related-urls

E-mail alerts

Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions

To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions

To request permission to re-use all or part of this article, use this link
http://cancerres.aacrjournals.org/content/61/17/6367.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.